These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 9333150)

  • 21. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type 1.
    Lathey JL; Pratt RD; Spector SA
    J Infect Dis; 1997 Jan; 175(1):231-2. PubMed ID: 8985228
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads.
    Pellegrin I; Legrand E; Neau D; Bonot P; Masquelier B; Pellegrin JL; Ragnaud JM; Bernard N; Fleury HJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(5):438-47. PubMed ID: 8605588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors.
    González N; McKee K; Lynch RM; Georgiev IS; Jimenez L; Grau E; Yuste E; Kwong PD; Mascola JR; Alcamí J
    PLoS One; 2018; 13(3):e0193773. PubMed ID: 29558468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission.
    Lathey JL; Tsou J; Brinker K; Hsia K; Meyer WA; Spector SA
    J Infect Dis; 1999 Aug; 180(2):344-50. PubMed ID: 10395848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35).
    Zhou J; Montefiori DC
    Virology; 1996 Dec; 226(1):13-21. PubMed ID: 8941318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism.
    Marcelino JM; Borrego P; Nilsson C; Família C; Barroso H; Maltez F; Doroana M; Antunes F; Quintas A; Taveira N
    AIDS; 2012 Nov; 26(18):2275-84. PubMed ID: 23151495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.
    Freund NT; Wang H; Scharf L; Nogueira L; Horwitz JA; Bar-On Y; Golijanin J; Sievers SA; Sok D; Cai H; Cesar Lorenzi JC; Halper-Stromberg A; Toth I; Piechocka-Trocha A; Gristick HB; van Gils MJ; Sanders RW; Wang LX; Seaman MS; Burton DR; Gazumyan A; Walker BD; West AP; Bjorkman PJ; Nussenzweig MC
    Sci Transl Med; 2017 Jan; 9(373):. PubMed ID: 28100831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients.
    Burrer R; Salmon-Ceron D; Richert S; Pancino G; Spiridon G; Haessig S; Roques V; Barre-Sinoussi F; Aubertin AM; Moog C
    J Virol; 2001 Jun; 75(11):5421-4. PubMed ID: 11333928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors.
    Zhang YJ; Fracasso C; Fiore JR; Björndal A; Angarano G; Gringeri A; Fenyö EM
    J Infect Dis; 1997 Nov; 176(5):1180-7. PubMed ID: 9359717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.
    Verrier F; Nádas A; Gorny MK; Zolla-Pazner S
    J Virol; 2001 Oct; 75(19):9177-86. PubMed ID: 11533181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women.
    Mkhize NN; Durgiah R; Ashley V; Archary D; Garrett NJ; Karim QA; Karim SS; Moore PL; Yates N; Passmore JA; Tomaras GD; Morris L
    AIDS; 2016 Apr; 30(7):1005-14. PubMed ID: 26836790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system.
    Dong M; Zhang PF; Grieder F; Lee J; Krishnamurthy G; VanCott T; Broder C; Polonis VR; Yu XF; Shao Y; Faix D; Valente P; Quinnan GV
    J Virol; 2003 Mar; 77(5):3119-30. PubMed ID: 12584337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients.
    Moja P; Tranchat C; Tchou I; Pozzetto B; Lucht F; Desgranges C; Genin C
    J Infect Dis; 2000 May; 181(5):1607-13. PubMed ID: 10823760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
    Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
    J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.
    Tomaras GD; Yates NL; Liu P; Qin L; Fouda GG; Chavez LL; Decamp AC; Parks RJ; Ashley VC; Lucas JT; Cohen M; Eron J; Hicks CB; Liao HX; Self SG; Landucci G; Forthal DN; Weinhold KJ; Keele BF; Hahn BH; Greenberg ML; Morris L; Karim SS; Blattner WA; Montefiori DC; Shaw GM; Perelson AS; Haynes BF
    J Virol; 2008 Dec; 82(24):12449-63. PubMed ID: 18842730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.
    Sather DN; Armann J; Ching LK; Mavrantoni A; Sellhorn G; Caldwell Z; Yu X; Wood B; Self S; Kalams S; Stamatatos L
    J Virol; 2009 Jan; 83(2):757-69. PubMed ID: 18987148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
    Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
    J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.